title: The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
abstract: Monoclonal antibodies have demonstrated enormous potential as new classes of drugs that confer great benefits to patients, and more than 40 therapeutic antibodies have already been approved for clinical use. In particular, the past 5 years might be recognized as the period guiding the new era for "engineered antibodies," with the successful approval of numerous antibody-drug conjugates, bispecific antibodies, and glyco-engineered antibodies for clinical applications. In this review, we summarize the development of antibody engineering technologies that are proving their concepts in the clinic, mainly focusing on the latest trends in defucosylated antibody technologies.
authors.affiliation: Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo, 100-8185, Japan.
authors.forename: Rinpei
authors.initials: R
authors.lastname: Niwa
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Satoh
mesh_terms: D018033:Antibodies, Bispecific / Q000096:biosynthesis* / Q000737:chemistry / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000737:chemistry / Q000627:therapeutic use; D000918:Antibody Specificity; D006031:Glycosylation; D018796:Immunoconjugates / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D011487:Protein Conformation; D015202:Protein Engineering; D011499:Protein Processing, Post-Translational; D013329:Structure-Activity Relationship; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates
keywords: Therapeutic antibody; biotechnology; cancer; conjugation; glycosylation; immunology; immunotherapy; targeted drug delivery